FDA is­sues CRL to small Dutch biotech's breast can­cer ADC as OS fig­ures fail to im­press

The FDA has bat­ted back an ap­pli­ca­tion for a po­ten­tial breast can­cer ther­a­py.

US reg­u­la­tors is­sued a com­plete re­sponse let­ter to the small Dutch biotech Byondis, re­ject­ing its pitch for an an­ti­body-drug con­ju­gate com­bin­ing Her­ceptin with the com­pa­ny’s ex­per­i­men­tal drug duo­car­mazine. Byondis did not say what prompt­ed the CRL, not­ing on­ly in a press re­lease that the FDA want­ed more in­for­ma­tion re­quir­ing “time and re­sources that ex­tend be­yond the cur­rent eval­u­a­tion pe­ri­od.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER